International Journal of Cancer Management

Published by: Kowsar

Ureteral Reimplantation or Percutaneous Nephrostomy: Which One Is Better in Management of Complete Ureteral Obstruction Due to Advanced Prostate Cancer?

Babak Javanmard 1 , Mohammadreza Yousefi 2 , * , Mohammad Yaghoobi 3 , Amin Hasanzadeh Hadad 3 , Maryam Amani 4 , Behruz Fadavi 2 and Morteza Fallah Karkan 2
Authors Information
1 Laser Application in Medical Sciences Research Center(LAMSRC) Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
2 MD, Resident of Urology, Department of Urology. Shohada-e-Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
3 MD., Urologist, Department of Urology, Shohada-e-Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
4 MD., Resident of Pathology, Department of Pathology. Be’sat Hospital, Hamedan University of Medical Sciences, Hamedan, IR Iran
Article information
  • International Journal of Cancer Management: September 2017, 10 (9); e6074
  • Published Online: September 30, 2017
  • Article Type: Research Article
  • Received: March 16, 2016
  • Revised: November 15, 2016
  • Accepted: August 26, 2017
  • DOI: 10.5812/ijcm.6074

To Cite: Javanmard B, Yousefi M, Yaghoobi M, Hasanzadeh Hadad A, Amani M, et al. Ureteral Reimplantation or Percutaneous Nephrostomy: Which One Is Better in Management of Complete Ureteral Obstruction Due to Advanced Prostate Cancer?, Int J Cancer Manag. 2017 ; 10(9):e6074. doi: 10.5812/ijcm.6074.

Copyright © 2017, Cancer Research Center (CRC), Shahid Beheshti University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
5. Conclusions
  • 1. Friedlander JI, Duty BD, Okeke Z, Smith AD. Obstructive uropathy from locally advanced and metastatic prostate cancer: an old problem with new therapies. J Endourol. 2012;26(2):102-9. doi: 10.1089/end.2011.0227. [PubMed: 22192109].
  • 2. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA. 1993;270(8):948-54. [PubMed: 7688438].
  • 3. Nariculam J, Murphy DG, Jenner C, Sellars N, Gwyther S, Gordon SG. Nephrostomy insertion for patients with bilateral ureteric obstruction caused by prostate cancer. Br J Radiol. 2009;82(979):571-6. doi: 10.1259/bjr/38306763. [PubMed: 19153185].
  • 4. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300. doi: 10.3322/caac.20073. [PubMed: 20610543].
  • 5. Kouba E, Wallen EM, Pruthi RS. Management of ureteral obstruction due to advanced malignancy: optimizing therapeutic and palliative outcomes. J Urol. 2008;180(2):444-50. doi: 10.1016/j.juro.2008.04.008. [PubMed: 18550089].
  • 6. Russo P. Ureteral obstruction and stents: still a difficult problem for patients and urologists alike. J Urol. 2005;174(6):2088. doi: 10.1097/01.ju.0000187105.30751.77. [PubMed: 16280733].
  • 7. Spencer BA, Insel BJ, Hershman DL, Benson MC, Neugut AI. Racial disparities in the use of palliative therapy for ureteral obstruction among elderly patients with advanced prostate cancer. Support Care Cancer. 2013;21(5):1303-11. doi: 10.1007/s00520-012-1666-6. [PubMed: 23292697].
  • 8. Ganatra AM, Loughlin KR. The management of malignant ureteral obstruction treated with ureteral stents. J Urol. 2005;174(6):2125-8. doi: 10.1097/01.ju.0000181807.56114.b7. [PubMed: 16280741].
  • 9. Wong LM, Cleeve LK, Milner AD, Pitman AG. Malignant ureteral obstruction: outcomes after intervention. Have things changed?. J Urol. 2007;178(1):178-83. discussion 183. doi: 10.1016/j.juro.2007.03.026. [PubMed: 17499300].
  • 10. Leff RG, King DG. Ureteroneocystostomy for bilateral ureteral obstruction in carcinoma of prostate. Urology. 1978;11(6):633-5. [PubMed: 675934].
  • 11. Kihl B, Bratt CG. Reimplantation of the ureter in prostatic carcinoma associated with bilateral ureteric obstruction. Br J Urol. 1981;53(4):349-52. [PubMed: 7260550].
  • 12. Aravantinos E, Anagnostou T, Karatzas AD, Papakonstantinou W, Samarinas M, Melekos MD. Percutaneous nephrostomy in patients with tumors of advanced stage: treatment dilemmas and impact on clinical course and quality of life. J Endourol. 2007;21(11):1297-302. doi: 10.1089/end.2006.0104. [PubMed: 18042018].
  • 13. Clarke NW. Management of the spectrum of hormone refractory prostate cancer. Eur Urol. 2006;50(3):428-38. discussion 438-9. doi: 10.1016/j.eururo.2006.05.017. [PubMed: 16797118].
  • 14. Paul AB, Love C, Chisholm GD. The management of bilateral ureteric obstruction and renal failure in advanced prostate cancer. Br J Urol. 1994;74(5):642-5. [PubMed: 7827817].
  • 15. Dowling RA, Carrasco CH, Babaian RJ. Percutaneous urinary diversion in patients with hormone-refractory prostate cancer. Urology. 1991;37(2):89-91. [PubMed: 1992595].
  • 16. Fossa SD. Palliative pelvic radiotherapy in patients with hormone-resistant prostatic cancer. Prog Clin Biol Res. 1987;243B:479-85. [PubMed: 2443925].
  • 17. Khan AU, Utz DC. Clinical management of carcinoma of prostate, associated with bilateral ureteral obstruction. J Urol. 1975;113(6):816-9. [PubMed: 1152155].
  • 18. Wilson JR, Urwin GH, Stower MJ. The role of percutaneous nephrostomy in malignant ureteric obstruction. Ann R Coll Surg Engl. 2005;87(1):21-4. doi: 10.1308/1478708051432. [PubMed: 15720902].
  • 19. Markowitz DM, Wong KT, Laffey KJ, Bixon R, Nagler HM, Martin EC. Maintaining quality of life after palliative diversion for malignant ureteral obstruction. Urol Radiol. 1989;11(3):129-32. [PubMed: 2480679].
  • 20. Lau MW, Temperley DE, Mehta S, Johnson RJ, Barnard RJ, Clarke NW. Urinary tract obstruction and nephrostomy drainage in pelvic malignant disease. Br J Urol. 1995;76(5):565-9. [PubMed: 8535673].
  • 21. Ku JH, Lee SW, Jeon HG, Kim HH, Oh SJ. Percutaneous nephrostomy versus indwelling ureteral stents in the management of extrinsic ureteral obstruction in advanced malignancies: are there differences?. Urology. 2004;64(5):895-9. doi: 10.1016/j.urology.2004.06.029. [PubMed: 15533473].
  • 22. Eyre RC, Benotti PN, Bothe A, Cady B, Steele GJ. Management of the urinary tract involved by recurrent cancer. Arch Surg. 1987;122(4):493-8. [PubMed: 2436596].
  • 23. Joshi HB, Adams S, Obadeyi OO, Rao PN. Nephrostomy tube or 'JJ' ureteric stent in ureteric obstruction: assessment of patient perspectives using quality-of-life survey and utility analysis. Eur Urol. 2001;39(6):695-701. [PubMed: 11464060].
  • 24. Ahmad I, Saeed Pansota M, Tariq M, Shahzad Saleem M, Ali Tabassum S, Hussain A. Comparison between Double J (DJ) Ureteral Stenting and Percutaneous Nephrostomy (PCN) in Obstructive Uropathy. Pak J Med Sci. 2013;29(3):725-9. [PubMed: 24353616].
  • 25. Feng MI, Bellman GC, Shapiro CE. Management of ureteral obstruction secondary to pelvic malignancies. J Endourol. 1999;13(7):521-4. doi: 10.1089/end.1999.13.521. [PubMed: 10569528].
  • 26. Song Y, Fei X, Song Y. Percutaneous nephrostomy versus indwelling ureteral stent in the management of gynecological malignancies. Int J Gynecol Cancer. 2012;22(4):697-702. doi: 10.1097/IGC.0b013e318243b475. [PubMed: 22315095].
  • 27. Ishioka J, Kageyama Y, Inoue M, Higashi Y, Kihara K. Prognostic model for predicting survival after palliative urinary diversion for ureteral obstruction: analysis of 140 cases. J Urol. 2008;180(2):618-21. discussion 621. doi: 10.1016/j.juro.2008.04.011. [PubMed: 18554655].
  • 28. Oefelein MG. Prognostic significance of obstructive uropathy in advanced prostate cancer. Urology. 2004;63(6):1117-21. doi: 10.1016/j.urology.2004.01.026. [PubMed: 15183963].
  • 29. Colombel M, Mallame W, Abbou CC. Influence of urological complications on the prognosis of prostate cancer. Eur Urol. 1997;31 Suppl 3:21-4. [PubMed: 9101211].
  • 30. Allen DJ, Longhorn SE, Philp T, Smith RD, Choong S. Percutaneous urinary drainage and ureteric stenting in malignant disease. Clin Oncol (R Coll Radiol). 2010;22(9):733-9. doi: 10.1016/j.clon.2010.07.004. [PubMed: 20728326].
  • 31. Radecka E, Magnusson M, Magnusson A. Survival time and period of catheterization in patients treated with percutaneous nephrostomy for urinary obstruction due to malignancy. Acta Radiol. 2006;47(3):328-31. [PubMed: 16613316].
  • 32. Gandaglia G, Karakiewicz PI, Briganti A, Passoni NM, Schiffmann J, Trudeau V. Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer. Eur Urol. 2015;68(2):325-34. doi: 10.1016/j.eururo.2014.07.020. [PubMed: 25108577].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments